In 2001, Arthritis Australia approached us to ascertain whether it would be possible to estimate the economic impact of arthritis in Australia. We developed a method that involved estimating from epidemiological and demographic data the prevalence of different types of arthritis, compiling information on health system expenditures across acute, primary and allied care, as well as losses in national production due to reduced workforce participation and absenteeism of people with arthritis and their careers.
The Prevalence, Cost of Disease Burden of Arthritis in Australia was thus the first of our 'cost of illness' studies, which have become a signature offering of our health economics practice. We have since undertaken hundreds of studies across five continents and over 70 therapeutic areas including for various cancers, cardiovascular diseases, diabetes, respiratory and gastro-intestinal conditions, vision and hearing loss, dementia, sleep disorders and Parkinson's disease. Many of the findings have been published in peer-reviewed journals, presented at international conferences, and used in iconic public health campaigns – with substantial media and public policy impact.
Key examples have been our Cost of obesity reports in 2005 and 2008 which generated media for four years in Australia, as well as a 20-country study in 2012-13 on the cost of four eye diseases which was used to assist in the global campaign to eradicate preventable blindness, and a 9-country study on the cost of four heart conditions in 2015-17 which was used to raise awareness across Latin American policy makers, clinicians, patient bodies and other stakeholders to better prevent and treat heart disease and save lives. Most recently our work since 2012 for the Butterfly Foundation in Australia on the cost of eating disorders and cost effective intervention has led to 2017-18 Federal Government investments in better models of care for this vulnerable group.
Find out more